News | November 10, 2021
Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Subscribe To Our Newsletter & Stay Updated
